NCT03334513 is a clinical trial of Bevacizumab in Retinopathy of Prematurity, sponsored by San Ni Chen.

Who is sponsoring NCT03334513?

NCT03334513 is sponsored by San Ni Chen.

What drugs are being tested in NCT03334513?

Interventions in NCT03334513: Bevacizumab, Ranibizumab.

What condition does NCT03334513 study?

NCT03334513 studies Retinopathy of Prematurity.

Is NCT03334513 still recruiting?

NCT03334513 is currently completed. Last updated 7 November 2017.

Last reviewed 2017-11-07 · How we verify

NCT03334513

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refractive Error and Biometry in Retinopathy of Prematurity

Completed Last updated 7 November 2017

What this trial tests

trial testing Bevacizumab in Retinopathy of Prematurity in 35 participants. Completed in 1 April 2014.

Timeline

1 April 2011

Primary endpoint
1 April 2014

1 April 2014

Quick facts

Lead sponsor	San Ni Chen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	35
Start date	1 April 2011
Primary completion	1 April 2014
Estimated completion	1 April 2014

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Ranibizumab — full drug profile →

Conditions studied

Retinopathy of Prematurity — all drugs for Retinopathy of Prematurity →

Sponsor

San Ni Chen

Who can join

Adults 3 to 3, any sex, with Retinopathy of Prematurity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age.
Chen YC, Chen SN, Yang BC, Lee KH, et al · · 2018 · cited 16× · PMID 29713524 · DOI 10.1155/2018/4565216

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Retinopathy of Prematurity

Currently open trials in the same condition.

NCT05558059 — Imaging Retinal Vasculature in Infant Eyes · recruiting
NCT06672913 — Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study · NA · recruiting
NCT06109285 — Validation of i-ROP DL to Detect More Than Mild ROP · NA · active not recruiting
NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
NCT06265363 — Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey. · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03334513 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by San Ni Chen
Last refreshed: 7 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03334513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing